Biogen Idec Names Susan H. Alexander as Executive Vice President and General Counsel.CAMBRIDGE, Mass. -- Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BIIB BIIB Basic Imagery Interpretation Brief ) announced today that Susan H. Alexander has been appointed Executive Vice President, General Counsel and Corporate Secretary. She reports to James C. Mullen, Chief Executive Officer of Biogen Idec. "With more than 20 years of legal experience and in-depth knowledge of life science, high-tech and chemical manufacturing industries manufacturing industries npl → industrias fpl manufactureras manufacturing industries npl → industries fpl de transformation , European legal issues and mergers and acquisitions activity, Susan will be a valued leader as we continue to execute on our plan for long-term growth," said Mullen. Alexander joins Biogen Idec from PAREXEL International, a global leader in assisting pharmaceutical, biotechnology and medical device companies bringing new products to market, where she served as Senior Vice President, General Counsel and Corporate Secretary. From 1995 to 2003, she was the General Counsel and Secretary at IONA Technologies IONA Technologies, NASDAQ: IONA, began life as a campus company in Trinity College, Dublin and was founded by Chris Horn, Annrai O'Toole, Colin Newman and Seán Baker.[1][2] IONA maintains headquarter offices in Dublin, Boston and Tokyo. and Counsel at Cabot Corporation. In addition, Alexander previously served as a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne. About Biogen Idec Biogen Idec creates new standards of care Standards of care are medical or psychological treatment guidelines, and can be general or specific. They specify appropriate treatment protocols based on scientific evidence, and collaboration between medical and/or psychological professionals involved in the treatment of a given in oncology, neurology and immunology. As a global leader in the development, manufacturing and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labelling, press releases and additional information about the company, please visit www.biogenidec.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion